A utilidade diagnóstica e prognóstica dos péptidos natriuréticos em patologia médica
Palavras-chave:
BNP, Medicina Interna, PrognósticoResumo
Os péptidos natriuréticos, BNP e NT-proBNP, estão elevados em
doentes que apresentam aumento da tensão na parede miocárdica. A sua determinação tem sido amplamente utilizada no
diagnóstico de insuficiência cardíaca em doentes com dispneia.
Os níveis séricos de BNP e NT-proBNP são afectados por variáveis
como a idade, o género, o índice de massa corporal e a função
renal. Mais recentemente, tem sido investigada a elevação dos
seus níveis em doentes com síndrome coronária aguda, doença
aterosclerótica coronária estável, doença pulmonar obstrutiva
crónica, hipertensão pulmonar e sépsis. Nesta revisão abordamos
o valor diagnóstico e prognóstico dos péptidos natriuréticos no
espectro de patologias do âmbito da medicina interna.
Downloads
Referências
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28: 89-94.
Kangawa K, Matsuo H. Purification and complete amino acid sequence of a -human atrial natriuretic polypeptide ( a-hANP). Biochem Biophys Res Commun 1984; 118: 131-139.
Hall C. Essential biochemistry and physiology of (NTpro) BNP. Eur J Heart Fail 2004; 6: 257–260.
Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. J Clin Invest 1995; 96: 1280–1287.
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825– 832.
Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999; 59: 132– 142.
McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72– 80.
Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287.
Wijeyaratne CN, Moult PJA. The effect of a human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive
subjects. J Clin Endocrinol Metab 1993; 76: 343-346.
Schultz HD, Gardner DG, Deschepper CF, Coleridge HM, Coleridge JC. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol 1988; 155: R6-R13.
Yang RH, Jin HK, Wyss JM, Chen YF, Oparil S. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension 1992; 19: 198-205.
Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986; 324: 473-476.
Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987; 326:6 97-98.
Burrell LM, Lambert HJ, Baylis PH. Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans. Am J Physiol 1991; 260: R475-R479.
Steele MK, Gardner DG, Xie PL, Schultz HD. Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow. Am J Physiol 1991; 260: R1145-R1151.
Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002; 39: 202-209.
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161-167.
Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004; 350: 647-654.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40: 976-982.
Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006; 47: 345-353.
McCullough PA, Duc P, Omland T, et al. B-type Natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 2003; 41: 571– 579.
Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin Chim Acta. 2005; 361: 167-175.
Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254 -258.
Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43: 1590-1595.
Sarzani R, Dessi-Fulgheri P, Paci VM et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996; 19: 581- 585.
Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathological aspects. J Nephrol 1998; 11: 296 -299.
Licata G, Volpe M, Scaglione R et al. Salt-regulating hormones in young normotensive obese subjects: effects of saline load. Hypertension 1994; 23: 120 -124.
Morabito D, Vallotton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Investig Med 2001; 49: 310 -318.
Krauser DG, Lloyd-Jones DM, Chae CU et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005; 149: 744-750.
Masson S, Latini R, Anand IS et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (ValHeFT) data. Clin Chem. 2006; 52: 1528-1538.
Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta. 2004; 341: 41-48.
El Mahmoud R, Alibay Y, Brun-Ney D et al. Type B natriuretic peptide (BNP) versus n-terminal type B natriuretic propeptide in the diagnosis of cardiac failure in the elderly over 75 population. Arch Mal Coeur Vaiss 2006; 99: 201-207.
Alibay Y, Beauchet A, El Mahmoud R et al. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother 2005; 59: 20-24.
Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.
Wijeysundera HC, Hansen MS, Stanton E, et al. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J 2003; 146: 291-297.
Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283.
Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments— comparison with neurohumoral factors. Circ J 2002; 66: 537-543.
Maeda K, Tsutamoto T,Wada A et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-391.
Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 2002; 113:
-219.
Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.
Heart 2001; 86: 21-26.
Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397.
Fonarow GC, Peacock WF, Phillips CO et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 1943-1950.
Januzzi JL, Sakhuja R, O’donoghue M et al. Utility of amino-terminal probrain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006; 166: 315-320.
de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021.
Sabatine S, Morrow DA, de Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760–1763.
Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-675.
Goetze JP, Gore A, Moller CH et al. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928-1930.
Toth M, Vuorinen KH, Vuolteenaho O et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994; 266: H1572-H1580.
Palumbo B, Siepi D, Lupattelli G et al. Usefulness of brain natriuretic peptide levels to discriminate patients with stable angina pectoris without and with electrocardiographic myocardial ischemia and patients with healed myocardial infarction. Am J Cardiol 2004; 94: 780-783.
Sabatine MS, Morrow DA, de Lemos JA et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44: 1988-1995.
Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci 1995; 88: 551-556.
Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICSTIMI 18. J Am Coll Cardiol 2003; 41: 1264–1272.
Brown AM, Sease KL, Robey JL, Shofer FS, Hollander JE. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann Emerg Med 2007; 49: 153-163.
Tateishi J, Masutani M, Ohyanagi M et al. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000; 23: 776-780.
Schnabel R, Lubos E, Rupprecht HJ et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47: 552-558.
Mueller C, Laule-Kilian K, Frana B et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 2006; 151: 471-477.
Ishii J, Nomura M, Ito M et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right
ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301: 19–30.
Leuchte HH, Neurohr C, Baumgartner R et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360–365.
Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med. 1999; 93: 507-514.
Leuchte HH, Baumgartner RA, Nounou ME et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173: 744-750.
Leuchte HH, Holzapfel M, Baumgartner RA et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764-770.
Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Itoh M, Amaha K. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997; 12: 66-71.
Karmpaliotis D, Kirtane AJ, Ruisi CP et al. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007; 131: 964-971.
Forfia P, Watkins S, Rame J et al. Relationship between B-type natriuretic peptides and pulmonary capilary wedge pressure in te intensive care unit. J Am Coll Cardiol 2005; 45: 1667-1671.
Charpentier J, Luyt CE, Fulla Y et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660-665.
Hoffmann U, Bruckmann M, Bertsch T et al. Increased plasma levels of NTproANP and NT-proBNP natriuretic peptide as markers of cardiac depression in septic patients[abstract]. J Am Coll Cardiol 2004; 43(Suppl A): 170A.
Januzzi JL, Morss A, Tung R et al. Natriuretic peptide testing for the evaluation of critically ill patients with septic shock in the intensive care unit: a prospective cohort study. Crit Care 2006; 10: R37.
Jardin F, Brun-Ney D, Auvert B, Beauchet A, Bourdarias JP. Sepsis-related cardiogenic shock. Crit Care Med 1990; 18: 1055-1060.
Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 1997; 23: 553-560.
Witthaut R, Busch C, Fraunberger P et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29: 1696-1702.
Tomaru Ki K, Arai M, Yokoyama T et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neo-natal rat cardiac myocytes. J Mol Cell Cardiol 2002; 34: 649-659.
Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-1430.
Court O, Kumar A, Parrillo JE, Kumar A. Myocardial depression in sepsis and septic shock. Crit Care 2002; 6: 500-508.
Perera PY, Qureshi N, Christ WJ, Stütz P, Vogel SN. Lipopolysaccharide and its analog antagonists display differential serum factor dependencies for induction of cytokine genes in murine macrophages. Infect Immun 1998; 66: 2562-2569.
Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1βmodulates de growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995, 96: 1093-9.
He Q, LaPointe MC. Interleukin-1β regulation of the human brain natriuretic peptide promotor involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999; 33: 283-289.
Kuwahara K, Saito Y, Harada M et al. Involvement of cardiotrophin-1 in cardiac myocite-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999; 100: 1116-1124.
Chua G, Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004; 8: R248-R250.
Brueckmann M, Huhle G, Lang S et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 112: 527-534.
Roch A, Allardet-Servent J, Michelet P et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33: 1001-1007.
Mokart D, Sannini A, Brun JP et al. NT-proBNP as an early prognostic factor in cancer patients developing septic shock. Crit Care 2007; 11: R37
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
